Testosterone Helps Bone Health in Prader-Willi
Males with Prader-Willi syndrome on testosterone saw steadier bone density and more lean mass over five years in a Dutch study.
Updated on Nov. 2, 2026 in Weight Loss

Testosterone therapy in males with Prader-Willi syndrome was associated with maintained bone mineral density and increased lean mass over follow-up, according to a real-world study of 59 males older than 14 years from three cohorts in the Netherlands. Behavior scores among treated participants did not change at 2 and 4 years compared with baseline, a finding relevant to families and clinicians weighing treatment for this rare genetic condition.
Why it matters
Prader-Willi syndrome often involves hypogonadism, which can prevent boys from reaching optimal bone mineral density during development, so whether therapy protects bone and body composition matters for long-term health. The study adds real-world evidence on outcomes such as bone density, lean mass, and behavior that families and clinicians can weigh alongside other considerations.
This real-world observational study followed 59 males with Prader-Willi syndrome older than 14 years across three Dutch cohorts, comparing outcomes in 44 testosterone users with baseline measurements. Bone density, body composition, and behavior were measured by DXA and the Developmental Behavior Checklist, with trabecular bone density showing a 0.28-point decline and lean mass a 0.47-point increase at 5 years.
The details
Testosterone was delivered in three forms among users: transdermal in 52.3%, intramuscular in 31.8%, and oral in 15.9%. Treatment use came from patient records, while body composition and bone mineral density were measured using DXA scans. Behavior was tracked with a parent- or carer-completed checklist, and 48.8% of users had challenging behavior before starting therapy.
Timeline
Study participants had a median age of 22.57 years at the time of analysis.
Behavior scores were compared with baseline at 2 and 4 years of follow-up.
Lean mass and lumbar spine bone density were measured at 5 years after testosterone initiation.
Health Landscape
Prader-Willi syndrome is a rare genetic condition in which hypogonadism is common, and evidence on hormone replacement has largely come from small groups and short follow-up. This observational study adds longer-term, real-world data on bone density and body composition to a limited research base that still lacks clear guidance on when to begin treatment.
If you or a family member has Prader-Willi syndrome, bone density and body composition are worth raising with a clinician, especially if hypogonadism has been identified. Treatment decisions, including whether and when to consider testosterone, are best made in conversation with a doctor familiar with the condition.
The takeaway
Real-world data suggest testosterone therapy may help preserve bone density and build lean mass in males with Prader-Willi syndrome without major behavioral changes in most users. Anyone considering treatment should discuss timing and expected benefits with their physician, since the study authors note more research is needed.
Further reading
For broader context on how body composition and metabolic health are studied, see our Weight Loss coverage.
Source note: This article includes information reported by Healio.


